(Q45175500)

10 December 2017

title

Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study (English)

1 reference

10 December 2017

main subject

phase II clinical trial

0 references

1 reference

13

David S Alberts

1 reference

10 December 2017

Mace L Rothenberg

1

1 reference

10 December 2017

P Y Liu

2

1 reference

10 December 2017

Sharon Wilczynski

3

1 reference

10 December 2017

William A Nahhas

4

1 reference

10 December 2017

Gaye L Winakur

5

1 reference

10 December 2017

Caroline S Jiang

6

1 reference

10 December 2017

Carol M Moinpour

7

1 reference

10 December 2017

Ben Lyons

8

1 reference

10 December 2017

Geoffrey R Weiss

9

1 reference

10 December 2017

James H Essell

10

1 reference

10 December 2017

Harriet O Smith

11

1 reference

10 December 2017

Maurie Markman

12

1 reference

10 December 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

10 December 2017

1 reference

10 December 2017

volume

95

1 reference

10 December 2017

issue

3

1 reference

10 December 2017

page(s)

506-512

1 reference

Epithelial ovarian cancer: prevention, diagnosis, and treatment

10 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.004

7 January 2021

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.004

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.004

Taxol: a novel investigational antimicrotubule agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.004

Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.004

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.004

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.004

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.004

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.004

Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.004

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.004

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.004

Vinorelbine (Navelbine): a third-generation vinca alkaloid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.004

Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.004

Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.004

Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.004

A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.004

A randomized clinical trial of home nursing care for lung cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.004

The MOS 36-ltem Short-Form Health Survey (SF-36)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.004

A phase II trial of piroxantrone in advanced ovarian carcinoma after failure of platinum-based chemotherapy: Southwest Oncology Group Study 8904

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.004

Phase II trial of didemnin-B in advanced epithelial ovarian cancer. A Southwest Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.004

Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: a Southwest Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.004

MIXTURE MODELS FOR THE JOINT DISTRIBUTION OF REPEATED MEASURES AND EVENT TIMES

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.004

The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: A review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.004

P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.004

10.1016/J.YGYNO.2004.09.004

7 January 2021

Identifiers

DOI

1 reference

10 December 2017

1 reference